Evidence map›Paper›PMID 37958771›Full record

ReviewInternational journal of molecular sciences2023

Therapeutic Effects of Mesenchymal Stromal Cells Require Mitochondrial Transfer and Quality Control.

Avinash Naraiah Mukkala, Mirjana Jerkic, Zahra Khan, Katalin Szaszi, Andras Kapus, Ori Rotstein

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Avinash Naraiah MukkalaUnity Health Toronto, The Keenan Research Centre for Biomedical Science of St. Michael's Hospital, University of Toronto, Toronto, ON M5B 1T8, Canada.
Mirjana JerkicUnity Health Toronto, The Keenan Research Centre for Biomedical Science of St. Michael's Hospital, University of Toronto, Toronto, ON M5B 1T8, Canada.ORCID 0000-0002-1714-3038
Zahra KhanUnity Health Toronto, The Keenan Research Centre for Biomedical Science of St. Michael's Hospital, University of Toronto, Toronto, ON M5B 1T8, Canada.
Katalin SzasziUnity Health Toronto, The Keenan Research Centre for Biomedical Science of St. Michael's Hospital, University of Toronto, Toronto, ON M5B 1T8, Canada.ORCID 0000-0002-2490-8422
Andras KapusUnity Health Toronto, The Keenan Research Centre for Biomedical Science of St. Michael's Hospital, University of Toronto, Toronto, ON M5B 1T8, Canada.
Ori RotsteinUnity Health Toronto, The Keenan Research Centre for Biomedical Science of St. Michael's Hospital, University of Toronto, Toronto, ON M5B 1T8, Canada.
St. Michael's Hospital · CA

Funding

CIHR 23766, PJT-180624, and PJT-178152
6 · The paper itself

Abstract

Due to their beneficial effects in an array of diseases, Mesenchymal Stromal Cells (MSCs) have been the focus of intense preclinical research and clinical implementation for decades. MSCs have multilineage differentiation capacity, support hematopoiesis, secrete pro-regenerative factors and exert immunoregulatory functions promoting homeostasis and the resolution of injury/inflammation. The main effects of MSCs include modulation of immune cells (macrophages, neutrophils, and lymphocytes), secretion of antimicrobial peptides, and transfer of mitochondria (Mt) to injured cells. These actions can be enhanced by priming (i.e., licensing) MSCs prior to exposure to deleterious microenvironments. Preclinical evidence suggests that MSCs can exert therapeutic effects in a variety of pathological states, including cardiac, respiratory, hepatic, renal, and neurological diseases. One of the key emerging beneficial actions of MSCs is the improvement of mitochondrial functions in the injured tissues by enhancing mitochondrial quality control (MQC). Recent advances in the understanding of cellular MQC, including mitochondrial biogenesis, mitophagy, fission, and fusion, helped uncover how MSCs enhance these processes. Specifically, MSCs have been suggested to regulate peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α)-dependent biogenesis, Parkin-dependent mitophagy, and Mitofusins (Mfn1/2) or Dynamin Related Protein-1 (Drp1)-mediated fission/fusion. In addition, previous studies also verified mitochondrial transfer from MSCs through tunneling nanotubes and via microvesicular transport. Combined, these effects improve mitochondrial functions, thereby contributing to the resolution of injury and inflammation. Thus, uncovering how MSCs affect MQC opens new therapeutic avenues for organ injury, and the transplantation of MSC-derived mitochondria to injured tissues might represent an attractive new therapeutic approach.

Indexed as

Mesenchymal Stem CellsNanotubesCell Membrane StructuresHumansInflammationMitochondriaTunneling Nanotubescell treatmentinjury resolutionmicrovesiclesmitochondriamitochondrial transfer

Identifiers

PMID37958771
PMCPMC10647450
OpenAlexW4388048619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.